Valuation: Cellnovo

Market Cap 2.44M 2.09M 1.95M 1.79M 3.35M 233M 3.4M 23.06M 8.99M 117M 9.15M 8.95M 387M P/E 2018 *
-0.15x
P/E 2019 * -
Enterprise Value 12.46M 10.67M 9.98M 9.14M 17.15M 1.19B 17.38M 118M 46M 599M 46.78M 45.76M 1.98B EV / Sales 2018
8.63x
EV / Sales 2019 * -
Free-Float
99.67%
Yield 2018 *
-
Yield 2019 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.68M
-2.28%-3.75%-34.30%+16.67% 17.35B
+3.56%+5.19% - - 13.44B
+0.58%-3.14%-27.22%-43.35% 8.86B
-1.06%-9.40%-13.90%+91.71% 7.36B
-2.04%-12.11%-54.08%+144.56% 3.63B
-1.12%-5.58%-45.17%-21.05% 2.33B
-1.43%-6.25%-42.50%-37.27% 1.8B
+2.68%-0.15%+32.57%+100.75% 1.68B
-0.26%-1.56%+9.38%+69.20% 1.45B
Average -0.14%-2.89%-21.90%+40.15% 5.79B
Weighted average by Cap. -0.05%-2.03%-28.07%+28.29%

Financials

2018 2019 *
Net sales 3.32M 2.85M 2.66M 2.44M 4.57M 318M 4.63M 31.46M 12.27M 160M 12.47M 12.2M 528M -
Net income -15.94M -13.65M -12.78M -11.69M -21.95M -1.53B -22.24M -151M -58.86M -766M -59.85M -58.55M -2.53B -
Net Debt 10.02M 8.59M 8.03M 7.35M 13.8M 959M 13.98M 94.91M 37.01M 482M 37.63M 36.81M 1.59B -
Logo Cellnovo
Cellnovo Group SA is a France-based company principally engaged in medical instrument manufacturing . The Company specialized in the development of a mobile system for managing type 1 diabetes. Its apparatus includes a cordless micro-pump (a patch pump), an integrated monitoring device and a cellular handset with touch screen with an embedded blood glucose meter. The Company system enables diabetics to live a normal life whilst closely monitoring their glycaemia, their use of insulin, their activity and their food intake.
Employees
-
  1. Stock Market
  2. Stocks
  3. CLNV Stock